Patents by Inventor Daniel J. Powell, JR.

Daniel J. Powell, JR. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens
    Patent number: 11912753
    Abstract: The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor (UnivIR) that comprises an extracellular label binding domain, a transmembrane domain, and a cytoplasmic domain or otherwise an intracellular domain.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: February 27, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Nathalie Scholler, Katarzyna Urbanska, Daniel J. Powell, Jr.
  • Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
    Patent number: 11896614
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: February 13, 2024
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: David M. Barrett, Felipe Bedoya, Saba Ghassemi, Carl H. June, Bruce L. Levine, Jan J. Melenhorst, Michael C. Milone, Daniel J. Powell, Jr., Nathan Amar Singh, Zoe Zheng
  • METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS
    Publication number: 20230295296
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), and compositions and reaction mixtures comprising the same.
    Type: Application
    Filed: January 31, 2023
    Publication date: September 21, 2023
    Inventors: Felipe Bedoya, Saba Ghassemi, Carl H. June, Bruce L. Levine, Jan J. Melenhorst, Michael C. Milone, Daniel J. Powell, Jr., Zoe Zheng
  • USE OF TRANS-SIGNALING APPROACH IN CHIMERIC ANTIGEN RECEPTORS
    Publication number: 20230181643
    Abstract: The present invention provides compositions and methods for inducing a CAR mediated trans-signal in a T cell. The trans-signaling CAR T cells comprise a first CAR having a first signaling module and a second CAR having a distinct second signaling module. The present invention also provides cells comprising a plurality of types of CARs, wherein the plurality of types of CARs participate in trans-signaling to induce T cell activation.
    Type: Application
    Filed: October 20, 2022
    Publication date: June 15, 2023
    Inventors: Daniel J. Powell, Jr., Carl H. June
  • QUANTITATIVE CONTROL OF ACTIVITY OF ENGINEERED CELLS EXPRESSING SPYCATCHER AND SPYTAG UNIVERSAL IMMUNE RECEPTORS
    Publication number: 20230103327
    Abstract: The invention provides methods for stimulating a universal immune receptor-mediated response in a mammal using cells engineered to express a universal immune receptor that comprises an adaptor molecule, such as a SpyCatcher or a SpyTag moiety, a transmembrane domain, and an intracellular domain for T cell activation.
    Type: Application
    Filed: January 23, 2021
    Publication date: April 6, 2023
    Inventors: Daniel J. Powell, Jr., Andrew Tsourkas, Nicholas Minutolo
  • Use of trans-signaling approach in chimeric antigen receptors
    Patent number: 11484552
    Abstract: The present invention provides compositions and methods for inducing a CAR mediated trans-signal in a T cell. The trans-signaling CAR T cells comprise a first CAR having a first signaling module and a second CAR having a distinct second signaling module. The present invention also provides cells comprising a plurality of types of CARs, wherein the plurality of types of CARs participate in trans-signaling to induce T cell activation.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: November 1, 2022
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Daniel J. Powell, Jr., Carl H. June
  • Fully-human T-cell receptor specific for the 369-377 epitope derived from the Her2/Neu (ERBB2) receptor protein
    Publication number: 20220332787
    Abstract: The present invention relates to compositions and methods for treating HER2/Neu (ERBB2) expressing cancer cells. In some embodiments, the invention includes an isolated T cell receptor (TCR) having high affinity for and that specifically binds ERBB2369-377 epitope on a target cell. Other embodiments include a T cell or a population of T cells modified to express ERBB2-specific TCR. Further embodiments include methods of using ERBB2-specific TCR gene transfer for treating ERBB2 expressing cancer cells. Also included are methods and pharmaceutical compositions comprising the modified T cells for adoptive therapy.
    Type: Application
    Filed: April 29, 2022
    Publication date: October 20, 2022
    Inventor: Daniel J. Powell, Jr.
  • TREATMENT OF A CANINE CD20 POSITIVE DISEASE OR CONDITION USING A CANINE CD20-SPECIFIC CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20220168351
    Abstract: The present invention relates to compositions and methods for the treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor. One aspect includes a modified canine T cells and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity in canine.
    Type: Application
    Filed: August 31, 2021
    Publication date: June 2, 2022
    Inventors: Nicola MASON, Daniel J. POWELL, JR., Mohammed Kazim PANJWANI, Jenessa SMITH
  • Fully-human t-cell receptor specific for the 369-377 epitope derived from the Her2/neu (ERBB2) receptor protein
    Patent number: 11345735
    Abstract: The present invention relates to compositions and methods for treating HER2/Neu (ERBB2) expressing cancer cells. In some embodiments, the invention includes an isolated T cell receptor (TCR) having high affinity for and that specifically binds ERBB2369-377 epitope on a target cell. Other embodiments include a T cell or a population of T cells modified to express ERBB2-specific TCR. Further embodiments include methods of using ERBB2-specific TCR gene transfer for treating ERBB2 expressing cancer cells. Also included are methods and pharmaceutical compositions comprising the modified T cells for adoptive therapy.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: May 31, 2022
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventor: Daniel J. Powell, Jr.
  • CAR-EXPRESSING CELLS AGAINST MULTIPLE TUMOR ANTIGENS AND USES THEREOF
    Publication number: 20220089750
    Abstract: The invention provides compositions and methods for treating cancer by using immune effector cells (e.g., T cells, NK cells) engineered to conditionally express an agent which enhances the immune effector response of an immune effector cell that expresses a Chimeric Antigen Receptor (CAR). The conditional agents described herein include agents that target a cancer associated antigen, e.g., a CAR, agents that inhibit one or more checkpoint inhibitors of the immune response, and a cytokine.
    Type: Application
    Filed: September 29, 2021
    Publication date: March 24, 2022
    Inventors: Carl H. June, Daniel J. Powell, JR.
  • Car-expressing cells against multiple tumor antigens and uses thereof
    Patent number: 11161907
    Abstract: The invention provides compositions and methods for treating cancer by using immune effector cells (e.g., T cells, NK cells) engineered to conditionally express an agent which enhances the immune effector response of an immune effector cell that expresses a Chimeric Antigen Receptor (CAR). The conditional agents described herein include agents that target a cancer associated antigen, e.g., a CAR, agents that inhibit one or more checkpoint inhibitors of the immune response, and a cytokine.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: November 2, 2021
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Daniel J. Powell, Jr.
  • Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor
    Patent number: 11116795
    Abstract: The present invention relates to compositions and methods for the treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor. One aspect includes a modified canine T cells and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity in canine.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: September 14, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Nicola Mason, Daniel J. Powell, Jr., Mohammed Kazim Panjwani, Jenessa Smith
  • METHODS FOR IMPROVING THE EFFICACY AND EXPANSION OF IMMUNE CELLS
    Publication number: 20210246423
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.
    Type: Application
    Filed: September 18, 2020
    Publication date: August 12, 2021
    Inventors: Felipe Bedoya, Saba Ghassemi, Carl H. June, Omkar U. Kawalekar, Bruce L. Levine, Jan J. Melenhorst, Michael C. Milone, Daniel J. Powell, Jr., Zoe Zheng
  • HUMAN ALPHA-FOLATE RECEPTOR CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20210040202
    Abstract: The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having ?-folate receptor (FR?) binding domain and CD27 costimulatory domain to treat ovarian cancer. In an embodiment, the FR? binding domain is fully human, thereby preventing a host immune response.
    Type: Application
    Filed: October 21, 2020
    Publication date: February 11, 2021
    Inventor: Daniel J. Powell, Jr.
  • CD137 enrichment for efficient tumor infiltrating lymphocyte selection
    Patent number: 10900019
    Abstract: The invention includes compositions and methods to rapidly isolate and culture cells that are potent for use in adoptive immunotherapy. In one embodiment, the isolated cells of the invention are tumor infiltrating lymphocytes (TIL) that express CD137 (also known as 4-1BB and TNFSFR9).
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: January 26, 2021
    Assignee: The Trustees of The University of Pennsylvania
    Inventor: Daniel J. Powell, Jr.
  • Human alpha-folate receptor chimeric antigen receptor
    Patent number: 10844117
    Abstract: The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having ?-folate receptor (FR?) binding domain and CD27 costimulatory domain to treat ovarian cancer. In an embodiment, the FR? binding domain is fully human, thereby preventing a host immune response.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: November 24, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Daniel J. Powell, Jr.
  • Methods for improving the efficacy and expansion of immune cells
    Patent number: 10829735
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: November 10, 2020
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG
    Inventors: Felipe Bedoya, Saba Ghassemi, Carl H. June, Omkar U. Kawalekar, Bruce L. Levine, Jan J. Melenhorst, Michael Milone, Daniel J. Powell, Jr., Zoe Zheng
  • TREATMENT OF CANCER USING CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20200283729
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of a cancer associated antigen as described herein. The invention also relates to chimeric antigen receptor (CAR) specific to a cancer associated antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a cancer associated antigen as described herein.
    Type: Application
    Filed: October 11, 2019
    Publication date: September 10, 2020
    Inventors: Andreas Loew, Michael C. Milone, Daniel J. Powell, JR., Yangbing Zhao
  • Fully-human T-cell receptor specific for the 369-377 epitope derived from the Her2/Neu (ERBB2) receptor protein.
    Publication number: 20200223898
    Abstract: The present invention relates to compositions and methods for treating HER2/Neu (ERBB2) expressing cancer cells. In some embodiments, the invention includes an isolated T cell receptor (TCR) having high affinity for and that specifically binds ERBB2369-377 epitope on a target cell. Other embodiments include a T cell or a population of T cells modified to express ERBB2-specific TCR. Further embodiments include methods of using ERBB2-specific TCR gene transfer for treating ERBB2 expressing cancer cells. Also included are methods and pharmaceutical compositions comprising the modified T cells for adoptive therapy.
    Type: Application
    Filed: August 7, 2019
    Publication date: July 16, 2020
    Inventor: Daniel J. Powell, JR.
  • METHODS AND COMPOSITIONS OF A FOLLICLE STIMULATING HORMONE RECEPTOR IMMUNORECEPTOR OR CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20200199191
    Abstract: The present invention relates to compositions and methods for diagnosing and treating diseases, disorders or conditions associated with dysregulated expression of FSHR. The invention provides novel peptides that specifically bind to Follicle-stimulation hormone receptor (FSHR).
    Type: Application
    Filed: January 3, 2020
    Publication date: June 25, 2020
    Inventors: Daniel J. Powell, Jr., Caitlin Stashwick, Katarzyna Urbanska